Arecor Ltd

Arecor Ltd

Arecor Limited, located on the Cambridge Science Park, was established to provide formulation solutions to pharmaceutical and biotech companies developing drugs, vaccines, medical devices and diagnostics.

Telephone: +44 (0)1223 426 060
Address: Chesterford Research Park, Little Chesterford, Saffron Walden
Postcode: CB10 1XL
Country: United Kingdom
Website: http://www.arecor.com
Membership type:Corporate 6-20 (£250+VAT pa)

A UK-based leading formulation technology company delivering superior biopharmaceuticals via the innovative reformulation of proteins and peptides.

Arecor is a leader in developing superior biopharmaceuticals through the application of its innovative formulation technology platform. Arecor is leveraging this platform to develop a portfolio of proprietary products enabling improved treatments for diabetes care via the innovative reformulation of approved proteins and peptides.

In addition to its internal product portfolio, Arecor partners with leading pharmaceutical and biotech companies to deliver superior reformulations of their proprietary products, which would otherwise not be possible using conventional formulation science.

Arecor receives regulatory approval to initiate Phase I clinical trial for insulin product

Arecor Ltd, the specialty pharmaceutical company leveraging its innovative and proprietary formulation technology to develop superior treatments for a range of disease areas, including diabetes, today announces that a Phase I Clinical Trial Application (CTA) for product candidate AT247 has been approved by the Bundesamt für Sicherheit im Gesundheitswesen (BASG), the Austrian Federal Office for Safety in Health Care.

20 March 2019Read in full

Arecor appoints Chief Financial Officer

Arecor Limited, the specialty pharmaceutical company leveraging its innovative and proprietary formulation technology to develop superior treatments for a range of disease areas, including diabetes, is pleased to announce the appointment of Susan Lowther as Chief Financial Officer. Susan was appointed to the board with effect from 4th March 2019.

11 March 2019Read in full

Arecor logo

Super-fast-acting prandial insulin product receives £0.5m Innovate UK boost

Arecor Ltd, the specialty pharmaceutical company leveraging its innovative and proprietary formulation technology to develop superior treatments for a range of disease areas, including diabetes, is pleased to announce that it has been awarded a £0.5m grant from Innovate UK to advance its proprietary super-fast-acting prandial insulin product, AT270.

13 February 2019Read in full

Arecor logo

Arecor featured by the highly regarded industry publication, Scrip

Arecor Limited, the specialty pharmaceutical company leveraging its innovative and proprietary formulation technology to develop superior treatments for a range of disease areas, including diabetes, is pleased to announce that a feature profile by the highly regarded industry publication, SCRIP, is now available for viewing.

24 January 2019Read in full

Arecor participates in PepTalk 2019’s Protein Science week in San Diego, CA, USA

Arecor Limited is pleased to announce its participation at PEPTalk 2019’s Protein Science Week. This leading international conference and one of the largest annual gatherings of over 1,300 protein science researchers in the world, will be held between January 14-18, 2019, at the Hilton Hotel, San Diego Bayfront, San Diego, California, USA.

10 January 2019Read in full

Arecor announces clinical trials application for ultra-rapid acting insulin product

Arecor Ltd, the specialty pharmaceutical company leveraging its innovative and proprietary formulation technology to develop superior treatments for a range of disease areas, including diabetes, is pleased to announce that the Company has filed a Clinical Trial Application (CTA) to conduct a Phase I study in Type 1 patients of its ultra-rapid acting insulin product, AT247.

4 January 2019Read in full

Arecor attends the 37TH annual JP Morgan Healthcare Conference

Arecor Ltd, the UK-based specialty pharmaceutical company that develops superior biopharmaceuticals through the application of an innovative formulation technology platform, will be attending the 37th Annual JP Morgan Healthcare Conference in San Francisco, California, next month.

14 December 2018Read in full

Arecor logo

Arecor successfully defends a key European Patent

Arecor successfully defends a key European patent in opposition proceedings on the subject of mitigation of aggregation of therapeutic proteins during storage.

31 October 2018Read in full

Arecor secures £6m investment for clinical development of its diabetes portfolio

Arecor Ltd, the UK-based leader in developing superior biopharmaceuticals through the application of an innovative formulation technology platform, today announces that it has secured £6 million of investment from new and existing investors for the clinical development of the Company’s speciality pharma portfolio of proprietary diabetes products.

10 September 2018Read in full

Arecor to give a short course and present at the Bioprocessing Summit, 13th-17th August 2018

Arecor Ltd, the UK-based leading formulation technology company focused on developing superior biopharmaceuticals via the innovative reformulation of proteins and peptides, is pleased to announce its participation at the Bioprocessing Summit, 13th-17th August 2018, at the Sheraton Boston Hotel, Boston, Massachusetts, USA.

9 August 2018Read in full

  1. 1
  2. 2
  3. 3
  4. 4
04/03/2019

Scientist & Senior Scientist

Arecor is seeking to recruit talented scientists and senior scientists who are passionate about science and its application to t...

Location: Within 25 m of Cambridge
Salary: Competitive
More Info